« previous next »
Pages: [1]   Go Down

Author Topic: Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis  (Read 35 times)

Ketua Dobbs

  • Administrator
  • Rank: Jr. Consultant
  • *****
  • Posts: 699
  • Ketua
    • DOBBS
  • Field of Practice: CLINICAL HAEMATOLOGY
  • State: Selangor
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
« on: September 25, 2024, 01:41:39 AM »
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.
Source: Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
Logged
Let's make Bulletin Boards great again

Doctors Only Bulletin Board System (DOBBS)

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
« on: September 25, 2024, 01:41:39 AM »
Pages: [1]   Go Up
« previous next »
 


Powered by EzPortal